article Open AccessTop 1% cited
Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study
The Lancet Oncology · 2017 · Vol. 18(9) · pp. 1182–1191
Michael J. Overman✉(The University of Texas MD Anderson Cancer Center)Ray McDermott(St. Vincent's University Hospital)Joseph L. Leach(Allina Health)Sara Lonardi(Istituto Oncologico Veneto)Heinz‐Josef Lenz(USC Norris Comprehensive Cancer Center)Michael A. Morse(Duke Medical Center)Jayesh Desai(The Royal Melbourne Hospital)Andrew Hill(Trans Tasman Radiation Oncology Group)Michael D. Axelson(Bristol-Myers Squibb (United States))Rebecca A. Moss(Bristol-Myers Squibb (United States))Monica V. Goldberg(Bristol-Myers Squibb (United States))Z. Alexander Cao(Bristol-Myers Squibb (United States))Jean-Marie Ledeine(Bristol-Myers Squibb (Belgium))Gregory A. Maglinte(Bristol-Myers Squibb (United States))Scott Kopetz(The University of Texas MD Anderson Cancer Center)Thierry André(Assistance Publique – Hôpitaux de Paris)
Genetic factors in colorectal cancerCancer Immunotherapy and BiomarkersColorectal Cancer Treatments and StudiesNivolumabMedicineIrinotecanMicrosatellite instabilityColorectal cancerInternal medicineOncologyClinical endpointCancerOxaliplatin
MeSH terms
NivolumabAdultAntibodies, MonoclonalAntineoplastic AgentsCarcinomaFemaleHumansMaleMiddle AgedColorectal NeoplasmsTreatment OutcomeDisease-Free SurvivalMicrosatellite InstabilityDNA Mismatch RepairProgrammed Cell Death 1 Receptor
Citations
2,759
FWCI
168.21
field-weighted impact
References
37
Percentile
100%
vs. same field & year
Citations per year
Cited by
The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for the Management of Colon Cancer
Diseases of the Colon & Rectum · 2021 · 346 citations
Review of Indications of FDA-Approved Immune Checkpoint Inhibitors per NCCN Guidelines with the Level of Evidence
Cancers · 2020 · 1,166 citations
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
Journal of Clinical Oncology · 2019 · 2,871 citations
Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer
Journal of Clinical Oncology · 2018 · 2,023 citations
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
Annals of Oncology · 2021 · 1,029 citations
ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach
Annals of Oncology · 2019 · 1,029 citations
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
The Lancet Oncology · 2018 · 2,498 citations
Regulation and Function of the PD-L1 Checkpoint
Immunity · 2018 · 2,208 citations
References
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
New England Journal of Medicine · 2015 · 9,308 citations
Interpreting the significance of changes in health-related quality-of-life scores.
Journal of Clinical Oncology · 1998 · 2,890 citations
Phase I Study of Single-Agent Anti–Programmed Death-1 (MDX-1106) in Refractory Solid Tumors: Safety, Clinical Activity, Pharmacodynamics, and Immunologic Correlates
Journal of Clinical Oncology · 2010 · 2,913 citations
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
European Journal of Cancer · 2008 · 28,935 citations
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis
The Lancet Oncology · 2010 · 2,133 citations
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
JNCI Journal of the National Cancer Institute · 1993 · 15,705 citations
Genomic Correlates of Immune-Cell Infiltrates in Colorectal Carcinoma
Cell Reports · 2016 · 918 citations
Citation Network
How this paper connects to the literature. Drag to explore, click any node to open that paper.